Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma

• Main Authors: Alessia Villani, Gabriella Fabbrocini, Claudia Costa, Massimiliano Scalvenzi
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2020-04-01
• Series: Dermatology and Therapy
• Subjects: Adverse events; Basal cell carcinoma; Hedgehog inhibitors; Sonidegib
• Online Access: https://doi.org/10.1007/s13555-020-00378-8

Abstract Hedgehog inhibitors are promising alternative treatments for patients with advanced basal cell carcinomas. Sonidegib (Odomzo®), an oral smoothened (SMO) antagonist, is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who present recurrence following surgery or radiation therapy, or those who are not candidates for surgery or radiotherapy. Several studies and randomized controlled trials have been conducted to evaluate the efficacy, safety, and tolerability of this new molecule that has demonstrated a good response rate (44%). Grade 1–2 adverse events have also been reported. Further studies of real-world experiences are needed to better understand the correct management of the drug, alternative dosing regimens, and differences with other hedgehog inhibitors. This article provides a complete overview of the pharmacology and pharmacokinetics of sonidegib and a report of the trials and studies conducted. The most frequent adverse events and their correct management are also discussed.